Immune checkpoint inhibitors transformed lung cancer treatment, yet most patients who initially respond eventually relapse — and understanding exactly why has become one of oncology's most consequential puzzles. A comprehensive review in the Journal of Clinical Oncology now consolidates the field's mechanistic understanding of that resistance and maps the therapeutic landscape aimed at defeating it, with direct implications for the millions living with non-small cell lung cancer worldwide.
The review identifies several converging pathways through which tumors evade sustained immune attack. Mutations in β2-microglobulin and human leukocyte antigen genes impair the cancer cell's ability to display antigens to T cells, effectively rendering tumors invisible to the immune system after initial recognition. Simultaneously, T-cell exhaustion accumulates as chronic antigen exposure depletes effector function, while the tumor microenvironment undergoes metabolic and structural remodeling that actively suppresses immune activity. Specific oncogenic mutations — particularly in STK11 and KEAP1 — emerge as clinically meaningful drivers of resistance, creating metabolic contexts that blunt immunotherapy efficacy. Against this backdrop, the review catalogs next-generation checkpoint targets (TIGIT, LAG-3), epigenetic modulators including HDAC and DNMT inhibitors, AXL kinase inhibition, tumor-infiltrating lymphocyte therapies, CAR-T constructs, antibody-drug conjugates, and cancer vaccines as complementary arms of a resistance-breaking strategy.
This review is best understood as a field-mapping exercise rather than a report of new clinical data — its value lies in synthesizing fragmented findings into an actionable conceptual framework. Most cited strategies remain investigational, with few Phase III confirmations in the resistance setting specifically. Notably, the emphasis on biomarker-driven patient selection reflects a hard-won lesson: combining therapies without predictive stratification has historically produced toxicity without proportional benefit. The STK11/KEAP1 mutation angle is particularly worth watching, as these genomic subgroups represent a large, currently underserved population. Overall, this is a confirmatory and consolidating contribution — paradigm-shifting only insofar as it frames resistance as a tractable, multi-mechanism problem rather than an endpoint.